The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.
Healthcare
FDA Approves First New Molecular Entity Under National Priority Voucher Program
Source: FDA Press Releases — US Government, Public Domain